212 related articles for article (PubMed ID: 21719699)
1. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
[TBL] [Abstract][Full Text] [Related]
2. Novel point mutations attenuate autotaxin activity.
Koh E; Bandle RW; Roberts DD; Stracke ML; Clair T
Lipids Health Dis; 2009 Feb; 8():4. PubMed ID: 19222837
[TBL] [Abstract][Full Text] [Related]
3. Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs.
North EJ; Osborne DA; Bridson PK; Baker DL; Parrill AL
Bioorg Med Chem; 2009 May; 17(9):3433-42. PubMed ID: 19345587
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.
van Meeteren LA; Ruurs P; Christodoulou E; Goding JW; Takakusa H; Kikuchi K; Perrakis A; Nagano T; Moolenaar WH
J Biol Chem; 2005 Jun; 280(22):21155-61. PubMed ID: 15769751
[TBL] [Abstract][Full Text] [Related]
5. Characterization of non-lipid autotaxin inhibitors.
Hoeglund AB; Howard AL; Wanjala IW; Pham TC; Parrill AL; Baker DL
Bioorg Med Chem; 2010 Jan; 18(2):769-76. PubMed ID: 20005724
[TBL] [Abstract][Full Text] [Related]
6. Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D.
van Meeteren LA; Brinkmann V; Saulnier-Blache JS; Lynch KR; Moolenaar WH
Cancer Lett; 2008 Aug; 266(2):203-8. PubMed ID: 18378389
[TBL] [Abstract][Full Text] [Related]
7. Optimization of a pipemidic acid autotaxin inhibitor.
Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid.
Inoue M; Xie W; Matsushita Y; Chun J; Aoki J; Ueda H
Neuroscience; 2008 Mar; 152(2):296-8. PubMed ID: 18280050
[TBL] [Abstract][Full Text] [Related]
9. Development of an activity-based probe for autotaxin.
Cavalli S; Houben AJ; Albers HM; van Tilburg EW; de Ru A; Aoki J; van Veelen P; Moolenaar WH; Ovaa H
Chembiochem; 2010 Nov; 11(16):2311-7. PubMed ID: 20941725
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of autotaxin and insight into GPCR activation by lipid mediators.
Nishimasu H; Okudaira S; Hama K; Mihara E; Dohmae N; Inoue A; Ishitani R; Takagi J; Aoki J; Nureki O
Nat Struct Mol Biol; 2011 Feb; 18(2):205-12. PubMed ID: 21240269
[TBL] [Abstract][Full Text] [Related]
12. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.
Gupte R; Patil R; Liu J; Wang Y; Lee SC; Fujiwara Y; Fells J; Bolen AL; Emmons-Thompson K; Yates CR; Siddam A; Panupinthu N; Pham TC; Baker DL; Parrill AL; Mills GB; Tigyi G; Miller DD
ChemMedChem; 2011 May; 6(5):922-35. PubMed ID: 21465666
[TBL] [Abstract][Full Text] [Related]
13. Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency.
Salgado-Polo F; Fish A; Matsoukas MT; Heidebrecht T; Keune WJ; Perrakis A
J Biol Chem; 2018 Sep; 293(37):14312-14327. PubMed ID: 30026231
[TBL] [Abstract][Full Text] [Related]
14. Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis.
Li S; Wang B; Xu Y; Zhang J
Mol Cancer; 2011 Feb; 10():18. PubMed ID: 21314984
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells.
Gaetano CG; Samadi N; Tomsig JL; Macdonald TL; Lynch KR; Brindley DN
Mol Carcinog; 2009 Sep; 48(9):801-9. PubMed ID: 19204929
[TBL] [Abstract][Full Text] [Related]
16. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity.
Ferguson CG; Bigman CS; Richardson RD; van Meeteren LA; Moolenaar WH; Prestwich GD
Org Lett; 2006 May; 8(10):2023-6. PubMed ID: 16671772
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
North EJ; Howard AL; Wanjala IW; Pham TC; Baker DL; Parrill AL
J Med Chem; 2010 Apr; 53(8):3095-105. PubMed ID: 20349977
[TBL] [Abstract][Full Text] [Related]
18. Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells.
Zhang R; Wang J; Ma S; Huang Z; Zhang G
BMC Cell Biol; 2011 Mar; 12():11. PubMed ID: 21406114
[TBL] [Abstract][Full Text] [Related]
19. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.
van Meeteren LA; Ruurs P; Stortelers C; Bouwman P; van Rooijen MA; Pradère JP; Pettit TR; Wakelam MJ; Saulnier-Blache JS; Mummery CL; Moolenaar WH; Jonkers J
Mol Cell Biol; 2006 Jul; 26(13):5015-22. PubMed ID: 16782887
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
Federico L; Pamuklar Z; Smyth SS; Morris AJ
Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
